EUVIMEDSkopri EUVIMED
Open access · CC BY-NC-ND 4.0

Quantitative proteomics in medication‐related osteonecrosis of the jaw: A proof‐of‐concept study

Alejandro I Lorenzo-Pouso iD, Susana B Bravo, Javier Carballo, María Del Pilar Chantada-Vázquez, José Bagán, Leticia Bagán, Cintia M Chamorro-Petronacci iD, Mercedes Conde-Amboage, Rafael López-López, Abel García-García, Mario Pérez-Sayáns iD

Oral Diseases · 2023-07 · 29 (5) · 2117-2129

DOI: 10.1111/odi.14201 ↗

At a glance

Journal article in Oral Diseases, published online on 2022-04-16. Written by Alejandro I Lorenzo-Pouso and 10 co-authors. Institution: Oral Medicine, Oral Surgery and Implantology Unit, MedOralRes Group, University of Santiago de Compostela, Health Research Institute of Santiago de C…. Major MEDLINE topics: Bisphosphonate-Associated Osteonecrosis of the Jaw, Osteonecrosis, Bone Density Conservation Agents. Cited 18 times so far (Crossref); 30 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Objective

Medication‐related osteonecrosis of the jaw (MRONJ) is a paradoxical effect associated with bone‐modifying agents (BMAs) and other drugs. Currently, no valuable diagnostic or prognosis biomarkers exist. The goal of this research was to study MRONJ‐related salivary proteome. Materials and Methods This case–control aimed to study salivary proteome in MRONJ versus control groups (i) formed from BMAs consumers and (ii) healthy individuals to unravel biomarkers. Thirty‐eight samples of unstimulated whole saliva (18 MRONJ patients, 10 BMA consumers, and 10 healthy controls) were collected. Proteomic analysis by SWATH‐MS coupled with bioinformatics analysis was executed.

Results

A total of 586 proteins were identified, 175 proteins showed significant differences among MRONJ versus controls. SWATH‐MS revealed differentially expressed proteins among three groups, which have never been isolated. These proteins had distinct roles including cell envelope organization, positive regulation of vesicle fusion, positive regulation of receptor binding, or regulation of low‐density lipoprotein particle clearance. Integrative analysis prioritized 3 proteins (MMP9, AACT, and HBD). Under receiver‐operating characteristic analysis, this panel discriminated MRONJ with a sensitivity of 90% and a specificity of 78.9%.

Conclusion

These findings may inform a novel biomarker panel for MRONJ prediction or diagnosis. Nonetheless, further research is needed to validate this panel.

Subjects

MeSH terms (MEDLINE)

Bisphosphonate-Associated Osteonecrosis of the JawOsteonecrosisBone Density Conservation AgentsHumansProteomeProteomicsDenosumabBiomarkersDiphosphonates

Author keywords

MRONJbiomarker discoverypreventionprognosisproteomicssaliva

Substances

ProteomeDenosumabBiomarkersBone Density Conservation AgentsDiphosphonates

Authors and institutions

  • Oral Medicine, Oral Surgery and Implantology Unit, MedOralRes Group, University of Santiago de Compostela, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain.
  • Proteomic Unit, Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago de Compostela, Santiago de Compostela, Spain.
  • Department of Food Technology, Faculty of Sciences, University of Vigo-Ourense Campus, Vigo, Spain.
  • Department of Stomatology and Maxillofacial Surgery, University General Hospital of Valencia, Valencia, Spain.
  • Models of Optimization, Decision, Statistics and Applications Research Group (MODESTYA). Department of Statistics, Mathematical Analysis and Optimization, University of Santiago de Compostela, Santiago de Compostela, Sp…
  • Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago (IDIS), University Hospital Complex of Santiago de Compostela (SERGAS), Santiago de Compostela, Spain.

ORCID profiles: Alejandro I Lorenzo-Pouso, Cintia M Chamorro-Petronacci, Mario Pérez-Sayáns

Cite

APA

Lorenzo-Pouso, A. I., Bravo, S. B., Carballo, J., Chantada-Vázquez, M. D. P., Bagán, J., Bagán, L., Chamorro-Petronacci, C. M., Conde-Amboage, M., López-López, R., García-García, A., & Pérez-Sayáns, M. (2023). Quantitative proteomics in medication‐related osteonecrosis of the jaw: A proof‐of‐concept study. Oral Diseases, 29(5), 2117-2129. https://doi.org/10.1111/odi.14201

Vancouver

Lorenzo-Pouso AI, Bravo SB, Carballo J, Chantada-Vázquez MDP, Bagán J, Bagán L, et al. Quantitative proteomics in medication‐related osteonecrosis of the jaw: A proof‐of‐concept study. Oral Diseases. 2023;29(5):2117-2129. doi:10.1111/odi.14201

BibTeX
@article{LorenzoPouso2023,
  author = {Lorenzo-Pouso, Alejandro I and Bravo, Susana B and Carballo, Javier and Chantada-Vázquez, María Del Pilar and Bagán, José and Bagán, Leticia and Chamorro-Petronacci, Cintia M and Conde-Amboage, Mercedes and López-López, Rafael and García-García, Abel and Pérez-Sayáns, Mario},
  title = {Quantitative proteomics in medication‐related osteonecrosis of the jaw: A proof‐of‐concept study},
  journal = {Oral Diseases},
  year = {2023},
  volume = {29},
  number = {5},
  pages = {2117--2129},
  doi = {10.1111/odi.14201}
}
Start for free →